I'm not sure if its realistic, Pig, to expect efficacy data from the dose-finding stage of a trial that involves two approved drugs combined with our CORE NK cells. The focus is on safety first - and the company disclosed that publicly. For the dose-finding stage, a handful of patients is hardly going to produce data robust enough to warrant a standalone update. The goal was to establish whether CORE NK cells are safe in combination with Azacitidine and Ventoclax. That goal was established. Moving forward is where efficacy (esp. duration) will be determined.
Even if the data readout at the end of the dose-finding stage consists of clinical efficacy such PR or CR, I doubt it could be sufficient enough to be assessed as attributable to our NK cell therapy. Its not a monotherapy and, for that reason, the interim readout mid-year would warrant a standalone ASX update. However, it is not uncommon for biotech companies to withhold data from disclosure in preference to unveiling it at a prestigious conference such as ASH, which is in September. Besides, there are exceptions to ASX continuous disclosure rules, namely Listing Rule 3.1a -
https://www.asx.com.au/documents/rules/Chapter03.pdf
As for Rebecca's excitement about the ADVENT AML trial... it likely stems from the safety profile allowing our therapy to be treated in frontline patients and the knowledge she would have garnered about how the NK cells are behaving in the patients. "Promising" signals don't cut it anymore with the ASX... regardless of how significant such data may be in the eyes of medical experts. Besides, MD Anderson is the sponsor of the trial and there may be restrictions on when the efficacy data is to be released.
An update of a general nature about how the NK cells are performing in terms of expansion rates and persistence wouldn't go astray in this crap market and this end of town where fear and manipulation are rife. It wouldn't surprise me to see a bit of detail about the excitement behind the upcoming Qtrly Report.
As for the timing of data releases last year in context of the CR and suspension, the optics aren't great. That I agree with and will inevitably lead to negative speculation. But, its not much different to the very suspicious trading that has been occurring in CHM recently.
To say that the SP has declined by 83% since the start of Rebecca's leadership is both unfair and misleading, IMO. Sure, she joined the company as its COO upon Chow's resignation but the fact is she wasn't appointed CEO until early to mid-November. The SP has not declined 83% under her leadership. Finances have improved a lot since she was appointed CEO. Costs have been cut substantially, and $4 million in non-dilutionary funding has been added to the company's finances.
By all means, try to "keep the bastards honest" over disclosure and governance issues as that's anyone's prerogative but the fact is the company would be in consultation with its legal advisors as to what they are and aren't obliged to disclose. Was the release of the efficacy result from the other CORE NK trial during trading suspension, suspicious timing? IMO, its no more suspicious than the subject now being raised at this particular time. But, at least it could be raising CHM's exposure, I guess. Too bad it could be causing some SH anguish, right? In this tumultuous market, the biggest winners will be those with the money, temperament and fortitude to survive. Hopper and its sophisticated SH will keep the company afloat in light of its very promising pipeline of therapies. If retail SH can weather the storm by navigating the BS that exists on both sides, then they may come out unscathed and in profit. Trump is not making things easy... but it sure is for some.
Add to My Watchlist
What is My Watchlist?
